4 min read

How a Product NDC Change Impacts Your Rare Disease Patients

Whether it’s a new product formulation or a new company inheriting a product, it’s imperative to understand the impact.
Find out more on the potential impact a product NDC change may have on your patient population.

In the Rare Disease space, a product NDC may change for several reasons. Whether it’s a new product formulation on the market or a new company inheriting a previously established product, it’s imperative to think through the potential impact that a product NDC change may have on your established patient population. Here are a few things to consider that could reduce potential therapy gaps for patients when an NDC change is imminent.

Here are a few ways that utilizing a HUB with experienced clinical staff may be able to assist in helping to overcome/address authorization denials:

1. Existing Prior Authorizations/Authorization Renewals may be affected If the product requires a Prior Authorization from the payer, there is a high probability that the new NDC will cause claim rejections because it is unrecognized by the plan. This could cause patients to experience delays in receiving refills. For patients just starting treatment with the product, “drug not covered” rejections may occur until the payer has added the new NDC to their formulary. Also, if your product/program offers a “Bridge” program to allow for free-goods, you may see an uptake in utilization due to authorization denials, or product not covered rejections.

2. Communicating the ChangeAn NDC change requires mass communication to many parties involved. Payers, Patients, Healthcare Providers (HCP), even the Home Health Nurse (if applicable to your product) should be made aware of the change. There are several ways to partner with your HUB team to ensure the word is spread and that you have a targeted list identified so that the information is sent quickly and clearly.

If your product is limited distribution, it may be possible to obtain a targeted list of payers to expedite changes to formularies.

If your product is an injectable (self, or by HCP), will new injection training be involved? Your HUB team may be able to provide an exhaustive list of HCP’s or other caregivers that need to be re-trained.

You may be able to rely on your HUB team for mass mailings and/or call campaigns, to interact with targeted individuals that will potentially be impacted by any NDC change

3. Transition Timeline If the product is changing formulation, it’s important to know the timeline for phasing out the existing product and how long it may be still available to prescribers. Payers will need to allow for both the old and new NDC numbers in their system as pharmacies exhaust their existing inventory of product.

Additionally, if your product has a specific enrollment form, it’s also important to ensure that any changes in the formulation are updated so that prescribers are utilizing the most current prescription for dosing purposes. From a “Buy and Bill” perspective, will the NDC change also cause a drug pricing change? Alerting facilities to these changes and how they may impact pricing will be important to ensure their ongoing access to products.

These are just a few of the many things to consider when a product NDC change will occur. Ultimately, the primary goal of both the HUB team and Pharma partner should be to ensure a smooth transition for patients. Reducing potential delays or therapy gaps, while ensuring product access, is paramount to a successful transition. Be sure to engage your HUB management partners for additional insights and potential areas of impact for your product.

To learn more about how UBC puts the Patient First in our HUB programs, visit here.

Other Recent Posts

3 min read

UBC Appoints Anthony Luttenberger Chief Commercial Officer

Biopharma services industry veteran brings decades of experience spanning late-stage, clinical trials, & post-approval commercial support.
1 min read

UBC Listed as a Citeline Awards Finalist for Excellence in RWE

UBC is once again a finalist for the Citeline Awards, with our 2024 nomination coming in the Excellence in RWE category.
3 min read

UBC Recognized as a Citeline Awards Finalist Again

The Citeline Awards have recognized UBC & Seqster’s innovative collaboration as a shortlisted finalist for the Best Patient-Facing Technology Initiative Category in 2023.

Thank You for Connecting with UBC

Lorem ipsum dolor sit amet consectetur. Mi proin enim ipsum nascetur. Venenatis odio scelerisque non netus ac et pellentesque.

What You Can Expect Next

Lorem ipsum dolor sit amet consectetur. Cras aliquam erat eget magna sollicitudin.

Get Ready to Change Your Business

Lorem ipsum dolor sit amet consectetur. Mi proin enim ipsum nascetur. Venenatis odio scelerisque non netus ac et pellentesque.

Service Request

Bekki Bracken Brown

President & Chief Executive Officer

Bekki Bracken Brown serves as the President and CEO of UBC, guiding the company’s mission and values, including the improvement of access for patients to receive better outcomes. She oversees all aspects of UBC, such as operations, business growth strategy, sales and marketing, and acquisition support.

With over 20 years of industry experience, Ms. Brown brings knowledge from a successful career in senior management from her tenure at Quintiles, INC Research, and, most recently, with Syneos Health. She’s been a member of the North Carolina BIO Board of Directors since 2019. She is also a member of the Healthcare Businesswomen’s Association — Southeast Chapter and CHIEF, an organization that supports women executive leaders. Ms. Brown earned her bachelor’s degree at Duke University.